Wegovy, Novo Nordisk's obesity drug, showed higher weight loss in women with common heart disease compared to men in HFpEF trials.
Novo Nordisk's obesity drug, Wegovy, has shown higher weight loss in women with common heart disease compared to men with the same condition, according to an analysis of study data published in the Journal of the American College of Cardiology. The trials, involving 1,145 patients, focused on heart failure with preserved ejection fraction (HFpEF). Wegovy produced similar improvements in HFpEF symptoms, physical limitations, and exercise function regardless of sex.
June 23, 2024
6 Articles